Restore Mind Medicine

Categorical Failure of MM-110 Program July 2022 MindMed touted MM-110 as Phase II ready; without disclosing any immediate FDA risk to investors. August 2022 Source: Company SEDAR Filings, Company SEC Filings, MindMed Press Releases. See [3] MindMed terminated the MM-110 program after the FDA reiterated its request for months-to-years of preclinical safety trials which were first requested in 2015. As a result, MindMed lost over $19M in development costs, most of which was during Mr. Barrow's tenure as CDO/CEO. Moreover, MindMed lost a valuable drug asset. 38

View entire presentation